Anixa Biosciences (ANIX) said Monday that the Canadian Intellectual Property Office has issued a notice of allowance for a patent covering the company's ovarian cancer vaccine technology.
The patent, exclusively licensed from Cleveland Clinic, includes methods of administering an immunogenic composition comprising a nucleic acid encoding the anti-Mullerian hormone receptor 2 polypeptide, the company said.
Price: 2.72, Change: +0.02, Percent Change: +0.74
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.